Vincristine Sulfate — Drug Intelligence | 57 EU Trials

Filter these 57 trials by condition, phase, country and more.

Open in Search →

57 Registered trials

35 Recruiting

18 Completed trials

35 Sponsors

25 Countries

Phase III

Phase II

Phase III: 31 Phase II/III: 5 Phase II: 15 Phase I/II: 4 Phase IV: 1 Phase I (Other): 1

Oversight events:

7 serious breaches 25 temporary halts 7 urgent safety measures 2 unexpected events 4 corrective measures across 11 trials

View oversight register →

Indications tested

Diffuse large B-cell lymphoma 5 Follicular lymphoma 4 Neuroblastoma 3 Peripheral T-cell lymphoma unspecified 2 Follicle centre lymphoma follicular grade I II III 2 Follicular lymphoma stage II 1 Hepatocellular carcinoma 1 Mantle cell lymphoma stage II 1 Medulloblastoma 1 Primary mediastinal large B-cell lymphoma 1 B precursor type acute leukaemia 1 Ependymoma 1

Sponsors using this IMP

GPOH gGmbH 4 LYSARC 4 Celgene Corp. 3 Fondazione Gimema Franco Mandelli Onlus 3 Institut Curie 3 The University Of Birmingham 3 AbbVie Deutschland GmbH & Co. KG 2 Amgen Inc. 2 Charite Universitaetsmedizin Berlin KöR 2 Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting 2 Karolinska University Hospital 2 Novartis Pharma AG 2

All trials — page 2

57 total

Benefit of transplantation after Complete Response In Patients with T-cell lymphoma Recruiting

2022-501710-62-02 Phase IV 2 countries Lysarc
A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults wi… Recruiting

2022-501187-18-00 Phase III 2 countries University Of Saarland
The study's aim is to treat adult patients affected by Ph-like ALL, a Philadelphianegative ALL subtype, with a combination of the tyrosine k… Recruiting

2023-510240-20-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma Recruiting

2022-501180-40-00 Phase III 8 countries GPOH gGmbH
SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years. Recruiting

2024-510578-25-00 Phase III 10 countries The University Of Birmingham
RETINO 2018: conservative treatment for retinoblastoma: efficacy of the new management strategies and visual outcome Recruiting

2024-514025-30-00 Phase II 1 country Institut Curie
FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma Recruiting

2024-510579-40-00 Phase I/II 16 countries The University Of Birmingham
An international trial for children with atypical teratoid/rhabdoid tumours (ATRT) Recruiting

2022-501456-28-00 Phase III 12 countries GPOH gGmbH
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Recruiting

2022-501050-11-01 Phase II/III 14 countries Karolinska University Hospital
SIOP RANDOMET 2017 Recruiting

2023-508926-91-00 Phase III 10 countries GPOH gGmbH
LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma Recruiting

2023-508101-24-00 Phase III 14 countries Universitaetsklinikum Muenster AöR
Paediatric Hepatic International Tumour Trial Recruiting

2024-516110-38-00 Phase III 10 countries The University Of Birmingham
SIOP Ependymoma II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependym… Recruiting

2024-512222-28-00 Phase II/III 13 countries Centre Leon Berard
Conservative treatment of patients with retinoblastoma Recruiting

2024-517275-21-00 Phase II 1 country Institut Curie
Study to treat adult patients with Very High-Risk T-cell Acute Lymphoblastic Leukemia (ALL) with Daratumumab in addition to the National ALL… Ended

2024-511627-34-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
A Study to Assess the Efficacy and Safety of Golcadomide and Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lympho… Ended

2024-511304-16-00 Phase II 5 countries Celgene Corp.
A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High-… Ended

2023-510178-15-00 Phase III 17 countries Celgene Corp.
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i… Ended

2023-506906-38-00 Phase III 17 countries AbbVie Deutschland GmbH & Co. KG
A randomized, open-label, multi-center phase III trial comparing tisagenlecleucel to standard of care in adult participants with relapsed or… Ended

2023-503452-27-00 Phase III 7 countries Novartis Pharma AG
LOGGIC/FIREFLY-2: DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients with Low-Grade Glioma Requiring First-Line Systemic Therapy Ended

2024-510742-13-00 Phase III 16 countries Day One Biopharmaceuticals Inc.
A study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in patients with relapsed/refractory Follicular L… Ended

2024-511594-30-00 Phase III 4 countries Kite Pharma Inc.
A Randomized Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults … Ended

2023-503640-14-00 Phase III 17 countries Amgen Inc.
VERLEN - Phase II, Open-Label Study evaluating efficacy of Lenalidomide and Tafasitamab combination associated to Rituximab in frontline Dif… Ended

2023-507286-25-00 Phase II 2 countries LYSARC
The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and… Ended

2023-508968-30-00 Phase III 1 country Fondazione Gimema Franco Mandelli Onlus

Showing 25–48 of 57 trials

← All drugs A–Z